Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Exclusive: Another PBOC Official Is Under Probe, Possibly Tied to Third-Party Payment
IPhone Manufacturer Gets Into Electric Cars Via Fiat Venture
Investors Cash Out of Online Lender Qudian’s After Guidance Withdrawal
LATEST
Property Giant Evergrande Pays 12% in New Bond Financing
More Virtual Banks to Switch On in Hong Kong
Geely’s Volvo Links Up With China Unicom on 5G for Self-Driving Cars
Investors Cash Out of Online Lender Qudian’s After Guidance Withdrawal
China-U.S. Trade Deal Hardly Addresses Issue of Technology Transfer
Tesla Eyes Design and Research Center for ‘Chinese-Style’ Cars
IPhone Manufacturer Gets Into Electric Cars Via Fiat Venture
Exclusive: Another PBOC Official Is Under Probe, Possibly Tied to Third-Party Payment
‘Chunyun’ Helps Travel-Related Apps Grow Their Active Users in December, Survey Shows
Rising Air Pollution Across China Clouds Clear Skies in Beijing and Shanghai: Report
Huawei Asks U.K. Developers to Help Build App Ecosystem Amid Android Ban
WeChat Tests Pay-to-Read Feature for Public Blogging Accounts
Listed Internet Firms Rally in Fourth Quarter
Beijing Media Company Enlight Announce One Billion Yuan Investment in Animation
JD.com Doubles Down on Smaller-Cities Expansion to Bolster 2020 Growth
Big China Tech Feasts, as Startups Go Hungry
Beyond Meat Shares Rise on Executive’s China Comments
Government Push on Electronic Toll Collection System Fuels Supplier Growth
Yum China Mulls Second Listing in Hong Kong, News Reports Say
PBOC Selects Six Pilot Projects Under Fintech Development Plan
China’s Rising Vaccine Star Struggles to Reassure Investors After Halting Production

By Zhao Runhua, Wang Luyao and Liu Denghui / Apr 09, 2019 03:42 PM / Business & Tech

Photo: VCG

Photo: VCG

A rising star in China’s biotech industry is now raising concerns about the country’s ability to produce its own vaccines.

Chongqing Zhifei Biological has halted the production of its own meningitis vaccine AC-Hib, the company announced last week – a move that may keep investors at bay.

The company’s previous license to produce the vaccine expired April 1, and it has yet to receive a new one, despite having applied for renewal in November, according to the company’s official statement.

Regulations stipulate that a company needs to apply for a license once every five years in order to produce a vaccine, and Zhifei’s last approval for AC-Hib came in 2014. It is not clear if its license’s renewal this time around has been postponed or rejected.

Zhifei still sells HPV vaccines developed by global giant MSD, with which it shares revenues for China sales, but the AC-Hib has been a major revenue channel for the company.

Industry watchers say Zhifei’s case signals the increasingly tight supervision of vaccine production after scandals caused nationwide concern. Last year, Changsheng Bio-Technology caused outrage after it was found to have produced and sold roughly 500,000 substandard vaccines for babies.

Zhifei booked a total 2018 revenue of 5.2 billion yuan ($744 million), up 289.4% year-on-year. And the company’s net profit climbed 235.8% to 1.5 billion yuan for the same period.

But even strong overall performance may not reassure investors – an 8 billion yuan market value of the company's stock in Shenzhen Growth Enterprise Market evaporated in just one day after company’s statement. Since then, the company’s stock has dropped over 10%.

Related: 4 Things to Know About China’s Vaccine Scandal

 


Share this article
Open WeChat and scan the QR code